Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHAD E MILLER

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1538373071
CMS profile
251165
Location
AUSTELL, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$62,390.73

144 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHAD E MILLER

NPI 1538373071 · CMS profile ID 251165

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

AUSTELL, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538373071?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHAD E MILLER, NPI 1538373071, CMS profile ID 251165. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538373071?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). CHAD E MILLER, NPI 1538373071, CMS profile ID 251165. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538373071?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
CHAD E MILLER, NPI 1538373071, CMS profile ID 251165, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1538373071?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

144 matching records · $62,390.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 144 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–144 of 144.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EKOS Corporation $112.4104/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694935231 CMS
PFIZER INC. $16.8304/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672575287 CMS
Bayer HealthCare Pharmaceuticals Inc. $105.9304/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628453599 CMS
Mylan Specialty L.P. $16.6404/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694772313 CMS
Actelion Pharmaceuticals US, Inc. $296.6104/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764197 CMS
Actelion Pharmaceuticals US, Inc. $107.6704/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764201 CMS
Actelion Pharmaceuticals US, Inc. $705.5804/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764205 CMS
Actelion Pharmaceuticals US, Inc. $3,150.0004/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764209 CMS
GlaxoSmithKline, LLC. $14.5904/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670705457 CMS
United Therapeutics Corporation $14.7304/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703103485 CMS
Janssen Pharmaceuticals, Inc $4.6404/09/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659031573 CMS
Sandoz Inc. $16.5804/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 639787519 CMS
Actelion Pharmaceuticals US, Inc. $100.1304/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764187 CMS
Actelion Pharmaceuticals US, Inc. $79.7003/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764157 CMS
Bayer HealthCare Pharmaceuticals Inc. $23.1503/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628475507 CMS
Electromed, Inc. $16.1003/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705237547 CMS
United Therapeutics Corporation $106.7503/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703103483 CMS
Circassia Pharmaceuticals Inc $23.9303/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660217557 CMS
Actelion Pharmaceuticals US, Inc. $120.3403/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764139 CMS
Actelion Pharmaceuticals US, Inc. $1,750.0003/13/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764143 CMS
United Therapeutics Corporation $168.5303/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703103481 CMS
Actelion Pharmaceuticals US, Inc. $115.4803/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764131 CMS
Actelion Pharmaceuticals US, Inc. $2,250.0003/07/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764135 CMS
AstraZeneca Pharmaceuticals LP $24.0903/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685880097 CMS
United Therapeutics Corporation $17.7003/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703103479 CMS
Actelion Pharmaceuticals US, Inc. $81.0802/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764121 CMS
Regeneron Healthcare Solutions, Inc. $19.9302/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673437965 CMS
AstraZeneca Pharmaceuticals LP $15.8102/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685320613 CMS
GlaxoSmithKline, LLC. $13.2202/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670422923 CMS
United Therapeutics Corporation $3.9902/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703103477 CMS
United Therapeutics Corporation $106.1302/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703103475 CMS
Alexion Pharmaceuticals, Inc. $13.1202/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695618927 CMS
Pulmonx Corporation $23.9202/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 690765883 CMS
Sunovion Pharmaceuticals Inc. $23.0202/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692376735 CMS
Actelion Pharmaceuticals US, Inc. $112.2501/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764097 CMS
Actelion Pharmaceuticals, Ltd $320.1601/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648626207 CMS
Actelion Pharmaceuticals, Ltd $34.2601/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648626211 CMS
Actelion Pharmaceuticals, Ltd $50.0001/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648626213 CMS
Actelion Pharmaceuticals, Ltd $12.5001/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648626215 CMS
Actelion Pharmaceuticals, Ltd $59.2501/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648626217 CMS
Actelion Pharmaceuticals, Ltd $865.2401/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648626221 CMS
Sandoz Inc. $18.8001/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 639787525 CMS
Janssen Pharmaceuticals, Inc $0.6001/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659030845 CMS
United Therapeutics Corporation $4.8901/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703103473 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $62,390.73 144
PY2020 $28,317.45 59
PY2021 $45,065.82 81
PY2022 $56,916.11 99
PY2023 $68,401.48 90
PY2024 $66,522.93 112
PY2025 $54,257.78 101

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $177,410.96 38
PY2024 Principal investigator $367,962.93 68
PY2023 Principal investigator $171,143.16 37
PY2022 Principal investigator $318,173.91 49
PY2021 Principal investigator $229,482.79 27
PY2020 Principal investigator $190,867.41 46
PY2019 Principal investigator $155,459.46 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

38 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $90,059.73 12/31/2025 Non-covered Recipient Entity
Piedmont Atlanta Hospital
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection F No dispute reported 06/30/2026 1232938890
Principal investigator 1 Janssen Research & Development, LLC $1,936.00 12/22/2025 Non-covered Recipient Entity
PIEDMONT HEALTHCARE INC
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175390194
Principal investigator 1 United Therapeutics Corporation $1,130.00 12/10/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242387449
Principal investigator 1 Janssen Research & Development, LLC $152.00 10/30/2025 Non-covered Recipient Entity
PIEDMONT HEALTHCARE INC
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175390258
Principal investigator 1 United Therapeutics Corporation $68.94 10/22/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242387441
Principal investigator 1 United Therapeutics Corporation $522.59 10/22/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242387443
Principal investigator 1 United Therapeutics Corporation $1,500.00 10/22/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242387455
Principal investigator 1 United Therapeutics Corporation $2,073.98 10/22/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242387471
Principal investigator 1 United Therapeutics Corporation $3,808.57 10/22/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242387477
Principal investigator 1 United Therapeutics Corporation $1,600.00 09/24/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242387461
Principal investigator 1 United Therapeutics Corporation $3,450.00 09/10/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242387475
Principal investigator 1 Janssen Research & Development, LLC $988.00 09/04/2025 Non-covered Recipient Entity
PIEDMONT HEALTHCARE INC
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175390161
Principal investigator 1 Janssen Research & Development, LLC $152.00 09/04/2025 Non-covered Recipient Entity
PIEDMONT HEALTHCARE INC
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175390246
Principal investigator 1 United Therapeutics Corporation $5,470.32 08/27/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242387481
Principal investigator 1 Janssen Research & Development, LLC $152.00 07/28/2025 Non-covered Recipient Entity
PIEDMONT HEALTHCARE INC
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175390277
Principal investigator 1 Janssen Research & Development, LLC $7,897.00 07/14/2025 Non-covered Recipient Entity
PIEDMONT HEALTHCARE INC
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175390234
Principal investigator 1 United Therapeutics Corporation $1,425.00 07/08/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242387453
Principal investigator 1 Janssen Research & Development, LLC $2,088.00 06/26/2025 Non-covered Recipient Entity
PIEDMONT HEALTHCARE INC
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175390252
Principal investigator 1 United Therapeutics Corporation $1,600.00 06/25/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242387459
Principal investigator 1 United Therapeutics Corporation $2,550.00 06/11/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242387473
Principal investigator 1 United Therapeutics Corporation $2,040.00 05/07/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242387469
Principal investigator 1 United Therapeutics Corporation $10,210.13 05/07/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242387483
Principal investigator 1 Janssen Research & Development, LLC $930.80 05/02/2025 Non-covered Recipient Entity
PIEDMONT HEALTHCARE INC
Prospective Multi Center double blind randomized active controlled triple dummy parallel group sequential adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan and tadalafil monotherapies with the corresponding fixed dose combination in subjects with pulmonary arterial hypertension PAH followed by an open label treatment period with macitentan and tadalafil fixed dose combination therapy No dispute reported 06/30/2026 1175390240
Principal investigator 1 Janssen Research & Development, LLC $304.00 04/28/2025 Non-covered Recipient Entity
PIEDMONT HEALTHCARE INC
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175390211
Principal investigator 1 United Therapeutics Corporation $1,350.00 04/23/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242387451
Principal investigator 1 United Therapeutics Corporation $1,600.00 04/23/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242387457
Principal investigator 1 Janssen Research & Development, LLC $122.20 03/31/2025 Non-covered Recipient Entity
PIEDMONT HEALTHCARE INC
Prospective Multi Center double blind randomized active controlled triple dummy parallel group sequential adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan and tadalafil monotherapies with the corresponding fixed dose combination in subjects with pulmonary arterial hypertension PAH followed by an open label treatment period with macitentan and tadalafil fixed dose combination therapy No dispute reported 06/30/2026 1175390265
Principal investigator 1 United Therapeutics Corporation $600.00 03/26/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242387445
Principal investigator 1 Janssen Research & Development, LLC $6,104.00 03/13/2025 Non-covered Recipient Entity
PIEDMONT HEALTHCARE INC
Prospective Multi Center double blind randomized active controlled triple dummy parallel group sequential adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan and tadalafil monotherapies with the corresponding fixed dose combination in subjects with pulmonary arterial hypertension PAH followed by an open label treatment period with macitentan and tadalafil fixed dose combination therapy No dispute reported 06/30/2026 1175390172
Principal investigator 1 Janssen Research & Development, LLC $905.65 03/13/2025 Non-covered Recipient Entity
PIEDMONT HEALTHCARE INC
Prospective Multi Center double blind randomized active controlled triple dummy parallel group sequential adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan and tadalafil monotherapies with the corresponding fixed dose combination in subjects with pulmonary arterial hypertension PAH followed by an open label treatment period with macitentan and tadalafil fixed dose combination therapy No dispute reported 06/30/2026 1175390271
Principal investigator 1 United Therapeutics Corporation $800.00 02/26/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242387447
Principal investigator 1 United Therapeutics Corporation $1,627.77 02/26/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242387463
Principal investigator 1 United Therapeutics Corporation $2,025.00 02/26/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242387467
Principal investigator 1 United Therapeutics Corporation $11,047.16 02/26/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242387485
Principal investigator 1 United Therapeutics Corporation $52.00 02/19/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242387427
Principal investigator 1 United Therapeutics Corporation $1,875.00 01/29/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242387465
Principal investigator 1 United Therapeutics Corporation $5,257.12 01/29/2025 Non-covered Recipient Entity
Piedmont Healthcare, Inc.
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242387479
Principal investigator 1 Janssen Research & Development, LLC $1,936.00 01/27/2025 Non-covered Recipient Entity
PIEDMONT HEALTHCARE INC
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175390204